These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 20868409)

  • 21. Finasteride revisited: Proscar for the prostate and Propecia for the pate.
    Harv Mens Health Watch; 2000 Jul; 4(12):1-4. PubMed ID: 10877872
    [No Abstract]   [Full Text] [Related]  

  • 22. [How effective is finasteride?].
    Krome S
    Dtsch Med Wochenschr; 2011 Feb; 136(8):354. PubMed ID: 21348003
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of finasteride on risk of prostate cancer: how little we really know.
    Rubin MA; Kantoff PW
    J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
    Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
    J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial.
    D'Amico AV; Roehrborn CG
    Lancet Oncol; 2007 Jan; 8(1):21-5. PubMed ID: 17196507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature.
    Boychenko O; Bernstein RM; Schweiger ES
    Cutis; 2012 Aug; 90(2):73-6. PubMed ID: 22988650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?].
    Spinucci G; Pasquali R
    Clin Ter; 1996 Jun; 147(6):305-15. PubMed ID: 8925640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies.
    Whiting DA
    Eur J Dermatol; 2001; 11(4):332-4. PubMed ID: 11399540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia.
    Ryu HJ; Kwon DY
    Dermatol Surg; 2014 May; 40(5):595-7. PubMed ID: 24533595
    [No Abstract]   [Full Text] [Related]  

  • 38. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia?
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baleanu BC; Paunica S
    Exp Dermatol; 2016 Jul; 25(7):557-8. PubMed ID: 26990657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
    Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
    JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Is tumour grade applicable to finasteride-treated prostate cancer?].
    Molinié V; Ruffion A; Allory Y; Leroy X; Cochand Priollet B; Paraf F; de la Taille A
    Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.